Alnylam Stock Crumbles After The FDA Unexpectedly Rejects Its Heart DrugInvestors Business Daily • 10/09/23
Alnylam to scrap sNDA for patisiran after receiving FDA complete response letterMarket Watch • 10/09/23
Alnylam Announces Receipt of Complete Response Letter from U.S. FDA for Supplemental New Drug Application for Patisiran for the Treatment of the Cardiomyopathy of ATTR AmyloidosisBusiness Wire • 10/09/23
Alnylam to Present Additional Data for Patisiran in Patients With the Cardiomyopathy of ATTR Amyloidosis, Including 24-Month Results From the APOLLO-B Phase 3 Study, at the Heart Failure Society of America Annual Scientific Meeting 2023Business Wire • 10/06/23
Alnylam Pharma Tumbles After FDA Advisors Dash Its Hopes Of Rivaling PfizerInvestors Business Daily • 09/14/23
Alnylam Pharmaceuticals shares fall after FDA advisers weigh in on heart-disease drugMarket Watch • 09/14/23
Alnylam Announces Positive Outcome of FDA Advisory Committee Meeting on Patisiran for the Treatment of the Cardiomyopathy of ATTR AmyloidosisBusiness Wire • 09/13/23
Alnylam Pharmaceuticals' stock to be halted Wednesday as FDA advisory panel reviews treatment for the Cardiomyopathy of ATTR AmyloidosisMarket Watch • 09/13/23
Alnylam Stock Trading Halted Today; FDA Advisory Committee to Review Supplemental New Drug Application for Patisiran for the Treatment of the Cardiomyopathy of ATTR AmyloidosisBusiness Wire • 09/13/23
Alnylam Continues To Deliver, But An Upcoming FDA Meeting Could Create Some VolatilitySeeking Alpha • 09/09/23
Alnylam Reports Positive Topline Results from KARDIA-1 Phase 2 Dose-Ranging Study of Zilebesiran, an Investigational RNAi Therapeutic in Development to Treat Hypertension in Patients at High Cardiovascular RiskBusiness Wire • 09/07/23
First Set of Recommendations Advocating for the Holistic Care of People Living with hATTR Amyloidosis Developed by International Panel of Patient Advocates and Healthcare ProfessionalsBusiness Wire • 09/06/23
Alnylam to Appeal Claim Construction Ruling on Two Patents Asserted Against ModernaBusiness Wire • 08/25/23
Alnylam (ALNY) Q2 Earnings: How Key Metrics Compare to Wall Street EstimatesZacks Investment Research • 08/03/23
Alnylam Pharmaceuticals (ALNY) Reports Q2 Loss, Lags Revenue EstimatesZacks Investment Research • 08/03/23